Περίληψη:
Background: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. Methods: A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements. Results: The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine-2 antagonists and 5-HT4 receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long-term prognosis of gastroparesis depends on the cause. Conclusions and Inferences: A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis. © 2021 John Wiley & Sons Ltd
Συγγραφείς:
Schol, J.
Wauters, L.
Dickman, R.
Drug, V.
Mulak, A.
Serra, J.
Enck, P.
Tack, J.
Accarino, A.
Barbara, G.
Bor, S.
Coffin, B.
Corsetti, M.
Dumitrascu, D.
Farmer, A.D.
Hauser, G.
Hausken, T.
Karamanolis, G.
Kestzhelyi, D.
Malagelada, C.
Milosavljevic, T.
O'Morain, C.
Papathanasopoulos, A.
Pohl, D.
Rumyantseva, D.
Sarnelli, G.
Savarino, E.
Sheptulin, A.
Smet, A.
Stengel, A.
Storonova, O.
Storr, M.
Törnblom, H.
Vanuytsel, T.
Velosa, M.
Waluga, M.
Zarate, N.
the ESNM Gastroparesis Consensus Group
Λέξεις-κλειδιά:
amitriptyline; antiemetic agent; buspirone; camicinal; cisapride; citalopram; dopamine 2 receptor blocking agent; erythromycin; escitalopram; itopride; metoclopramide; mirtazapine; mitemcinal; motilin receptor agonist; neurokinin 1 receptor antagonist; prokinetic agent; proton pump inhibitor; prucalopride; relamorelin; rikkunshito; serotonin 1A agonist; serotonin 3 antagonist; serotonin 4 agonist; serotonin noradrenalin reuptake inhibitor; serotonin uptake inhibitor; tandospirone; tegaserod; tricyclic antidepressant agent; ulimorelin; serotonin 4 antagonist, acupuncture; adult; Article; clinical practice; cognitive behavioral therapy; cohort analysis; consensus development; controlled study; coronavirus disease 2019; Delphi study; distress syndrome; drug efficacy; dysgeusia; dyspepsia; enteric feeding; enteropathy; eradication therapy; esophagogastroduodenoscopy; evidence based medicine; extrapyramidal symptom; fatigue; female; gastrectomy; headache; health care cost; human; human tissue; Likert scale; major clinical study; medical society; mindfulness; myotomy; nausea and vomiting; nutritional support; pathophysiology; prognosis; risk factor; satiety; stomach motility; stomach muscle; stomach obstruction; stomach paresis; stomach surgery; United States; consensus; digestive tract endoscopy; practice guideline; quality of life; stomach paresis, Consensus; Dopamine D2 Receptor Antagonists; Endoscopy, Digestive System; Gastroparesis; Humans; Nutritional Support; Quality of Life; Serotonin 5-HT4 Receptor Antagonists
